keyword
MENU ▼
Read by QxMD icon Read
search

Oritavancin

keyword
https://www.readbyqxmd.com/read/29208562/microbiological-factors-affecting-clostridium-difficile-recurrence
#1
REVIEW
C H Chilton, D S Pickering, J Freeman
BACKGROUND: Recurrent Clostridium difficile infection (rCDI) places a huge economic and practical burden on healthcare facilities. Furthermore, rCDI may impact quality of life, leaving patients in a 'rCDI cycle', and dependant on antibiotic therapy. AIMS: This article discusses the importance of microbiological factors in the development of rCDI. SOURCES: Literature was drawn from a search of PubMed from 2000 onwards with the search term "recurrent Clostridium difficile infection"; and further references quoted within these articles...
December 2, 2017: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/29121395/multiple-dose-oritavancin-evaluation-in-a-retrospective-cohort-of-patients-with-complicated-infections
#2
Lucas T Schulz, Emily Dworkin, Jennifer Dela-Pena, Warren E Rose
OBJECTIVE: Oritavancin is a lipoglycopeptide antibiotic approved for use in acute bacterial skin and skin structure infections as a single 1200 mg parenteral dose. Because of oritavancin's long half-life and broad gram-positive activity, interest in its use for other infections is high. METHODS: This study is a retrospective cohort evaluation of patients receiving oritavancin at a single academic medical center. All patients receiving more than one dose of oritavancin were included...
November 9, 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/29109163/evaluation-of-oritavancin-dosing-strategies-against-vancomycin-resistant-enterococcus-faecium-isolates-with-or-without-reduced-susceptibility-to-daptomycin-in-an-in-vitro-pharmacokinetic-pharmacodynamic-model
#3
Adam Belley, Francis A Arhin, Greg Moeck
Clinical development of nonsusceptibility to the lipopeptide antibiotic daptomycin remains a serious concern during therapy for infections caused by vancomycin-resistant Enterococcus faecium (VREfm). The long-acting lipoglycopeptide oritavancin exhibits potent in vitro activity against VREfm although its safety and efficacy in treating clinical VREfm infections have not been established. In this study, novel dosing regimens of daptomycin and oritavancin were assessed against both VREfm and daptomycin-nonsusceptible VREfm isolates in an in vitro pharmacokinetic/pharmacodynamic model...
November 6, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28942574/once-daily-treatments-for-methicillin-susceptible-staphylococcus-aureus-bacteremia-are-they-good-enough
#4
REVIEW
Sylvain A Lother, Natasha Press
PURPOSE OF THE REVIEW: Methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia is a common cause of morbidity and mortality. First-line treatment requires frequent daily doses of an anti-staphylococcal beta-lactam. However, some physicians prescribe simpler once-daily regimens to improve compliance and improve healthcare utilization. We reviewed the literature regarding advantages, pitfalls, and efficacy of once-daily treatment options for MSSA bacteremia. RECENT FINDINGS: Several once-daily antibiotics are effective in vitro against MSSA (ceftriaxone, daptomycin, telavancin, dalbavancin, oritavancin, tedizolid, ertapenem, fluoroquinolones, and others), but there is insufficient evidence to support these agents for MSSA bacteremia...
September 23, 2017: Current Infectious Disease Reports
https://www.readbyqxmd.com/read/28882727/newer-glycopeptide-antibiotics-for-treatment-of-complicated-skin-and-soft-tissue-infections-systematic-review-network-meta-analysis-and-cost-analysis
#5
REVIEW
R Agarwal, S M Bartsch, B J Kelly, M Prewitt, Y Liu, Y Chen, C A Umscheid
OBJECTIVES: Skin and soft tissue infections (SSTIs) carry significant economic burden, as well as morbidity and mortality, especially when caused by methicillin-resistant Staphylococcus aureus (MRSA). Several new MRSA-active antibiotics have been developed, including semisynthetic glycopeptides (telavancin, dalbavancin and oritavancin). Of these, dalbavancin and oritavancin offer extended dosing intervals. METHODS: We performed a systematic review, network meta-analysis and cost analysis to compare the newer glycopeptides to standard care and to each other for the treatment of complicated SSTIs (cSSTI)...
September 4, 2017: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/28733126/in-vitro-stepwise-selection-of-reduced-susceptibility-to-lipoglycopeptides-in-enterococci
#6
Francis F Arhin, David Lalonde Seguin, Adam Belley, Gregory Moeck
The propensity of oritavancin to select for stably elevated oritavancin minimum inhibitory concentrations (MICs) was studied by serial passaging of strains in broth containing oritavancin for 20days. Seven clinical strains of Enterococcus faecalis and E. faecium were studied; they included vancomycin-susceptible and both VanA and VanB vancomycin-resistant isolates. Stepwise oritavancin selection yielded stably elevated oritavancin MICs in six of the seven strains, with MIC increases ranging from 4-32-fold. By comparison, stepwise selection with comparator agents dalbavancin (4- to >128-fold MIC increases), telavancin (4-8-fold MIC increases) and daptomycin (4-32-fold MIC increases) also yielded selectants with elevated MICs of the respective agents...
July 1, 2017: Diagnostic Microbiology and Infectious Disease
https://www.readbyqxmd.com/read/28732783/future-trends-in-the-treatment-of-methicillin-resistant-staphylococcus-aureus-mrsa-infection-an-in-depth-review-of-newer-antibiotics-active-against-an-enduring-pathogen
#7
REVIEW
A M Bal, M Z David, J Garau, T Gottlieb, T Mazzei, F Scaglione, P Tattevin, I M Gould
Methicillin-resistant Staphylococcus aureus (MRSA) continues to be a major public health problem. Vancomycin and teicoplanin have been in clinical use for several decades but their drawbacks are well described. In the last 10 years, several antibiotics have been made available for clinical use. Daptomycin and linezolid have been extensively used during this period. Other agents such as ceftaroline, ceftobiprole, dalbavancin, oritavancin, tedizolid and telavancin have been approved by regulatory agencies since 2009...
September 2017: Journal of Global Antimicrobial Resistance
https://www.readbyqxmd.com/read/28666751/recently-approved-antibacterials-for-methicillin-resistant-staphylococcus-aureus-mrsa-and-other-gram-positive-pathogens-the-shock-of-the-new
#8
REVIEW
Michael Z David, Matthew Dryden, Thomas Gottlieb, Pierre Tattevin, Ian M Gould
A number of novel antimicrobial drugs with activity against Gram-positive bacterial pathogens have been licensed in the past 4 years. These drugs have the potential to enrich the group of intravenous drugs already available that are in common use against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci and other antibiotic-resistant Gram-positive pathogens. The advantages and disadvantages of these drugs are not yet fully appreciated. Here we review the five most promising newly approved compounds, namely ceftaroline, ceftobiprole, oritavancin, dalbavancin and tedizolid...
September 2017: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/28642145/new-and-improved-a-review-of-novel-antibiotics-for-gram-positive-bacteria
#9
REVIEW
M Abbas, M Paul, A Huttner
BACKGROUND: The number of antibiotics in the pipeline targeting Gram-positive pathogens has increased in recent years. AIMS: This narrative review aims to provide a summary of existing evidence on efficacy, microbiological spectrum and safety of novel systemic antibiotics that have either recently been licensed or completed phase III trials, and possess activity predominantly against Gram-positive organisms. SOURCES: A review of the published literature via the MEDLINE database was performed...
October 2017: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/28543367/successful-treatment-of-methicillin-susceptible-staphylococcus-aureus-osteomyelitis-with-oritavancin
#10
Dino J Delaportas, Sandy J Estrada, Matthew Darmelio
Staphylococcus aureus remains the most common causative pathogen in osteomyelitis. New or alternative therapies are often needed to treat S. aureus infections adequately in patients with drug allergies, treatment failures, or drug interactions. Oritavancin is a novel long-acting lipoglycopeptide approved by the U.S. Food and Drug Administration in 2014 for the treatment of acute bacterial skin and skin structure infections. With a terminal half-life of 8-10 days, oritavancin dosing regimens with infrequent parenteral administration now exist to treat infectious diseases such as osteomyelitis that would otherwise require daily dosing of intravenous antimicrobials for weeks; however, clinical experience is lacking...
August 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/28507244/inhibition-of-staphylococcus-aureus-cell-wall-biosynthesis-by-desleucyl-oritavancin-a-quantitative-peptidoglycan-composition-analysis-by-mass-spectrometry
#11
James D Chang, Erin E Foster, Aanchal N Thadani, Alejandro J Ramirez, Sung Joon Kim
Oritavancin is a lipoglycopeptide antibiotic that exhibits potent activities against vancomycin-resistant Gram-positive pathogens. Oritavancin differs from vancomycin by a hydrophobic side chain attached to the drug disaccharide, which forms a secondary binding site to enable oritavancin binding to the cross-linked peptidoglycan in the cell wall. The mode of action of secondary binding site was investigated by measuring the changes in the peptidoglycan composition of Staphylococcus aureus grown in the presence of desleucyl-oritavancin at subinhibitory concentration using liquid chromatography-mass spectrometry (LC-MS)...
August 1, 2017: Journal of Bacteriology
https://www.readbyqxmd.com/read/28480909/inhibition-of-d-ala-incorporation-into-wall-teichoic-acid-in-staphylococcus-aureus-by-desleucyl-oritavancin
#12
J Chang, L Coffman, S J Kim
The mode of action for desleucyl-oritavancin was investigated by adding an antibiotic to Staphylococcus aureus during its growth in a defined medium containing l,d-[1-(15)N]Ala and l-[1-(13)C]Lys, or d-[1-(15)N]Ala. (13)C{(15)N} and (15)N{(13)C} rotational-echo double resonance NMR determined that desleucyl-oritavancin inhibited the incorporation of d-[1-(15)N]Ala into wall teichoic acid.
May 18, 2017: Chemical Communications: Chem Comm
https://www.readbyqxmd.com/read/28480266/efficacy-and-safety-of-oritavancin-relative-to-vancomycin-for-patients-with-acute-bacterial-skin-and-skin-structure-infections-absssi-in-the-outpatient-setting-results-from-the-solo-clinical-trials
#13
Thomas P Lodise, Mark Redell, Shannon O Armstrong, Katherine A Sulham, G Ralph Corey
BACKGROUND: The objective of this analysis was to evaluate the efficacy and safety of oritavancin compared with vancomycin for patients with acute bacterial skin and skin structure infections (ABSSSIs) who received treatment in the outpatient setting in the Phase 3 SOLO clinical trials. METHODS: SOLO I and SOLO II were 2 identically designed comparative, multicenter, double-blind, randomized studies to evaluate the efficacy and safety of a single 1200-mg dose of intravenous (IV) oritavancin versus 7-10 days of twice-daily IV vancomycin for the treatment of ABSSSI...
2017: Open Forum Infectious Diseases
https://www.readbyqxmd.com/read/28406838/managing-acute-bacterial-skin-and-skin-structure-infections-focus-on-new-lipoglycopeptides
#14
Allison M Bell, S Travis King, Katie E Barber, Kim G Adcock, Jamie L Wagner, Kayla R Stover
Acute bacterial skin and skin structure infections (ABSSSI) are some of the most commonly encountered infections worldwide. Hospitalizations as a result of ABSSSI are associated with high mortality. This article discusses the role of oritavancin and dalbavancin, two new lipoglycopeptides, in the context of the other I.V. available standard therapy options.
May 12, 2017: Nurse Practitioner
https://www.readbyqxmd.com/read/28386776/real-world-experience-with-oritavancin-therapy-in-invasive-gram-positive-infections
#15
Cassie L Stewart, Michelle S Turner, Jeremy J Frens, Cynthia B Snider, Jordan R Smith
INTRODUCTION: Oritavancin is a novel lipoglycopeptide approved for acute bacterial skin and skin structure infections. The pharmacokinetic profile and convenient one-time dosing make oritavancin an enticing option for other serious Gram-positive infections requiring prolonged treatment courses. Unfortunately, data for using oritavancin in these populations are limited. METHODS: We report ten cases of oritavancin use for invasive Gram-positive infections in our health system, and provide a review of the currently available literature regarding oritavancin therapy for invasive infections...
June 2017: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/28368603/hidden-mode-of-action-of-glycopeptide-antibiotics-inhibition-of-wall-teichoic-acid-biosynthesis
#16
Manmilan Singh, James Chang, Lauryn Coffman, Sung Joon Kim
Glycopeptide antibiotics inhibit the peptidoglycan biosynthesis in Gram-positive bacteria by targeting lipid II. This prevents the recycling of bactoprenol phosphate, the lipid transporter that is shared by peptidoglycan and wall teichoic acid biosyntheses. In this study, we investigate the effects of glycopeptide antibiotics on peptidoglycan and wall teichoic acid biosynthesis. The incorporation of d-[1-(13)C]alanine, d-[(15)N]alanine, and l-[1-(13)C]lysine into peptidoglycan and wall teichoic acid in intact whole cells of Staphylococcus aureus was measured using (13)C{(15)N} and (15)N{(13)C} rotational-echo double resonance NMR...
April 27, 2017: Journal of Physical Chemistry. B
https://www.readbyqxmd.com/read/28273381/role-of-combination-antimicrobial-therapy-for-vancomycin-resistant-enterococcus-faecium-infections-review-of-the-current-evidence
#17
REVIEW
Juwon Yim, Jordan R Smith, Michael J Rybak
Enterococcus species are the second most common cause of nosocomial infections in the United States and are particularly concerning in critically ill patients with preexisting comorbid conditions. Rising resistance to antimicrobials that were historically used as front-line agents for treatment of enterococcal infections, such as ampicillin, vancomycin, and aminoglycosides, further complicates the treatment of these infections. Of particular concern are Enterococcus faecium strains that are associated with the highest rate of vancomycin resistance...
May 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/28221772/desleucyl-oritavancin-with-a-damaged-d-ala-d-ala-binding-site-inhibits-the-transpeptidation-step-of-cell-wall-biosynthesis-in-whole-cells-of-staphylococcus-aureus
#18
Sung Joon Kim, Manmilan Singh, Shasad Sharif, Jacob Schaefer
We have used solid-state nuclear magnetic resonance to characterize the exact nature of the dual mode of action of oritavancin in preventing cell-wall assembly in Staphylococcus aureus. Measurements performed on whole cells labeled selectively in vivo have established that des-N-methylleucyl-N-4-(4-fluorophenyl)benzyl-chloroeremomycin, an Edman degradation product of [(19)F]oritavancin, which has a damaged d-Ala-d-Ala binding aglycon, is a potent inhibitor of the transpeptidase activity of cell-wall biosynthesis...
March 14, 2017: Biochemistry
https://www.readbyqxmd.com/read/28159446/in-vitro-activity-of-oritavancin-against-gram-positive-pathogens-isolated-in-canadian-hospital-laboratories-from-2011-to-2015
#19
James A Karlowsky, Andrew J Walkty, Melanie R Baxter, Francis F Arhin, Gregory Moeck, Heather J Adam, George G Zhanel
Gram-positive bacterial pathogens isolated from patient specimens submitted to 15 Canadian hospital laboratories from 2011 to 2015 were tested in the coordinating laboratory for susceptibility to oritavancin and comparative antimicrobial agents using the Clinical and Laboratory Standards Institute M07-A10 (2015) broth microdilution method. Oritavancin's in vitro activity was equivalent to, or more potent than, vancomycin, daptomycin, linezolid, and tigecycline against methicillin-susceptible Staphylococcus aureus (n=2680; oritavancin MIC90, 0...
April 2017: Diagnostic Microbiology and Infectious Disease
https://www.readbyqxmd.com/read/28155918/surface-mediated-cooperative-interactions-of-drugs-enhance-mechanical-forces-for-antibiotic-action
#20
Joseph W Ndieyira, Joe Bailey, Samadhan B Patil, Manuel Vögtli, Matthew A Cooper, Chris Abell, Rachel A McKendry, Gabriel Aeppli
The alarming increase of pathogenic bacteria that are resistant to multiple antibiotics is now recognized as a major health issue fuelling demand for new drugs. Bacterial resistance is often caused by molecular changes at the bacterial surface, which alter the nature of specific drug-target interactions. Here, we identify a novel mechanism by which drug-target interactions in resistant bacteria can be enhanced. We examined the surface forces generated by four antibiotics; vancomycin, ristomycin, chloroeremomycin and oritavancin against drug-susceptible and drug-resistant targets on a cantilever and demonstrated significant differences in mechanical response when drug-resistant targets are challenged with different antibiotics although no significant differences were observed when using susceptible targets...
February 3, 2017: Scientific Reports
keyword
keyword
30796
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"